Nu Skin Enterprises, Inc. (NUS)

Nu Skin looks inexpensive on revenue and book-value multiples, but the operating trend remains challenged: FY2025 revenue declined and the latest 2026 quarter showed another double-digit year-over-year drop alongside weaker distributor/customer metrics. Earnings have swung mainly due to one-time items (a large business-sale gain in 2025, then major non-cash impairment/tax charges in 2026), so headline GAAP profitability is not a dependable indicator of ongoing performance. Cash flow and liquidity are still supportive, but have weakened, making this more of a watchlist/turnaround value situation than a steady defensive compounder.

Dominant catalyst is the bearish Q2 earnings print (2026-08-11, announced): revenue miss, FY26 guidance cut, and a $78.9M non-cash goodwill impairment, still being digested with no offsetting bullish catalyst and an empty forward calendar. Media sentiment delta is indeterminate (baseline layer unscorable, Sparse Baseline Rule); moderate red-flag cap applied for sharply deteriorating ≤14d sentiment with no bullish offset.

Weak bearish / bounce-only. Price 4.725 sits below the SMA20 (4.82), SMA50 (5.04) and far below the SMA200 (7.45); ADX14 at 40.15 signals a strong trend, and with price below all moving averages it reads as a strong DOWN trend. RSI14 44.02 and Williams %R -54.65 are neutral-weak; MACD is still below zero (line -0.11, signal -0.11) with the histogram just marginally positive (0.01) — momentum is stabilizing but not turned up. The 09-01/09-02 bounce attempt (4.55 → 4.83) was faded on 09-03 (-2.2% to 4.725). Structure remains damaged with only bounce potential, hence score 2. Independently, the action is blocked: qualitativeScore 2 < 3 (hard override gate) and 20-day average dollar volume ~$2.92M is below the $5M liquidity floor.